Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
83(16), P. 1511 - 1525
Published: April 1, 2024
Lipoprotein(a)
(Lp[a])
is
a
causal
genetic
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
There
are
limited
long-term
follow-up
data
from
large
U.S.
population
cohorts.
This
study
examined
the
relationship
of
Lp(a)
with
ASCVD
outcomes
in
large,
pooled,
multi-ethnic
cohort.
The
included
on
and
5
prospective
studies:
MESA
(Multi-Ethnic
Study
Atherosclerosis),
CARDIA
(Coronary
Artery
Risk
Development
Young
Adults),
JHS
(Jackson
Heart
Study),
FHS-OS
(Framingham
Study-Offspring),
ARIC
(Atherosclerosis
In
Communities).
levels
were
classified
basis
cohort-specific
percentiles.
Multivariable
Cox
regression
related
composite
incident
events
by
group
diabetes
status.
27,756
persons
without
previous
who
aged
20
to
79
years,
including
55.0%
women,
35.6%
Black
participants,
7.6%
patients
diabetes,
mean
21.1
years.
Compared
<50th
percentile,
50th
<75th,
75th
<90th,
≥90th
percentiles
had
adjusted
HRs
1.06
(95%
CI:
0.99-1.14),
1.18
1.09-1.28),
1.46
1.33-1.59),
respectively
events.
Elevated
predicted
similarly
group,
sex,
race
or
ethnic
groups,
but
more
strongly
vs
(interaction
P
=
0.0056),
percentile
1.92
1.50-2.45)
1.41
1.28-1.55),
respectively.
also
individually
myocardial
infarction,
revascularization,
stroke,
coronary
heart
death,
not
total
mortality.
shows,
pooled
cohort,
that
higher
associated
an
increased
risk,
diabetes.
Journal of Hypertension,
Journal Year:
2023,
Volume and Issue:
41(12), P. 1874 - 2071
Published: June 24, 2023
Document
Reviewers:
Luis
Alcocer
(Mexico),
Christina
Antza
(Greece),
Mustafa
Arici
(Turkey),
Eduardo
Barbosa
(Brazil),
Adel
Berbari
(Lebanon),
Luís
Bronze
(Portugal),
John
Chalmers
(Australia),
Tine
De
Backer
(Belgium),
Alejandro
de
la
Sierra
(Spain),
Kyriakos
Dimitriadis
Dorota
Drozdz
(Poland),
Béatrice
Duly-Bouhanick
(France),
Brent
M.
Egan
(USA),
Serap
Erdine
Claudio
Ferri
(Italy),
Slavomira
Filipova
(Slovak
Republic),
Anthony
Heagerty
(UK),
Michael
Hecht
Olsen
(Denmark),
Dagmara
Hering
Sang
Hyun
Ihm
(South
Korea),
Uday
Jadhav
(India),
Manolis
Kallistratos
Kazuomi
Kario
(Japan),
Vasilios
Kotsis
Adi
Leiba
(Israel),
Patricio
López-Jaramillo
(Colombia),
Hans-Peter
Marti
(Norway),
Terry
McCormack
Paolo
Mulatero
Dike
B.
Ojji
(Nigeria),
Sungha
Park
Priit
Pauklin
(Estonia),
Sabine
Perl
(Austria),
Arman
Postadzhian
(Bulgaria),
Aleksander
Prejbisz
Venkata
Ram
Ramiro
Sanchez
(Argentina),
Markus
Schlaich
Alta
Schutte
Cristina
Sekib
Sokolovic
(Bosnia
and
Herzegovina),
Jonas
Spaak
(Sweden),
Dimitrios
Terentes-Printzios
Bruno
Trimarco
Thomas
Unger
(The
Netherlands),
Bert-Jan
van
den
Born
Anna
Vachulova
Agostino
Virdis
Jiguang
Wang
(China),
Ulrich
Wenzel
(Germany),
Paul
Whelton
Jiri
Widimsky
(Czech
Jacek
Wolf
Grégoire
Wuerzner
(Switzerland),
Eugene
Yang
Yuqing
Zhang
(China).
New England Journal of Medicine,
Journal Year:
2022,
Volume and Issue:
387(20), P. 1855 - 1864
Published: Nov. 6, 2022
Lipoprotein(a)
is
a
presumed
risk
factor
for
atherosclerotic
cardiovascular
disease.
Olpasiran
small
interfering
RNA
that
reduces
lipoprotein(a)
synthesis
in
the
liver.
Journal of Clinical Apheresis,
Journal Year:
2023,
Volume and Issue:
38(2), P. 77 - 278
Published: April 1, 2023
The
American
Society
for
Apheresis
(ASFA)
Journal
of
Clinical
(JCA)
Special
Issue
Writing
Committee
is
charged
with
reviewing,
updating,
and
categorizing
indications
the
evidence-based
use
therapeutic
apheresis
(TA)
in
human
disease.
In
Ninth
Edition,
JCA
has
incorporated
systematic
review
approaches
grading
evidence
categorization
to
make
recommendations
on
a
wide
variety
diseases
conditions.
This
edition
largely
maintained
general
layout
concept
fact
sheet
introduced
Fourth
Edition
(2007).
Each
succinctly
summarizes
TA
specific
disease
or
medical
condition.
comprises
91
sheets
166
graded
categorized
indications.
includes
seven
new
sheets,
nine
existing
eight
changes
category
seeks
continue
serve
as
key
resource
that
guides
utilization
treatment
European Heart Journal,
Journal Year:
2023,
Volume and Issue:
44(25), P. 2277 - 2291
Published: May 2, 2023
Abstract
This
2023
statement
updates
clinical
guidance
for
homozygous
familial
hypercholesterolaemia
(HoFH),
explains
the
genetic
complexity,
and
provides
pragmatic
recommendations
to
address
inequities
in
HoFH
care
worldwide.
Key
strengths
include
updated
criteria
diagnosis
of
recommendation
prioritize
phenotypic
features
over
genotype.
Thus,
a
low-density
lipoprotein
cholesterol
(LDL-C)
>10
mmol/L
(>400
mg/dL)
is
suggestive
warrants
further
evaluation.
The
also
state-of-the
art
discussion
clinicians
interpreting
results
testing
family
planning
pregnancy.
Therapeutic
decisions
are
based
on
LDL-C
level.
Combination
LDL-C-lowering
therapy—both
pharmacologic
intervention
apheresis
(LA)—is
foundational.
Addition
novel,
efficacious
therapies
(i.e.
inhibitors
proprotein
convertase
subtilisin/kexin
type
9,
followed
by
evinacumab
and/or
lomitapide)
offers
potential
attain
goal
or
reduce
need
LA.
To
improve
around
world,
recommends
creation
national
screening
programmes,
education
awareness,
management
guidelines
that
account
local
realities
care,
including
access
specialist
centres,
treatments,
cost.
crucial
early
diagnosis,
better
improved
cardiovascular
health
patients
with
JAMA,
Journal Year:
2023,
Volume and Issue:
330(11), P. 1042 - 1042
Published: Aug. 28, 2023
Lipoprotein(a)
(Lp[a])
is
associated
with
atherosclerotic
disease
and
aortic
stenosis.
Lp(a)
forms
by
bonding
between
apolipoprotein(a)
(apo[a])
apo
B100.
Muvalaplin
an
orally
administered
small
molecule
that
inhibits
formation
blocking
the
apo(a)-apo
B100
interaction
while
avoiding
a
homologous
protein,
plasminogen.
Global Heart,
Journal Year:
2022,
Volume and Issue:
17(1), P. 75 - 75
Published: Oct. 14, 2022
Background:
Atherosclerotic
cardiovascular
diseases
(ASCVD)
including
myocardial
infarction,
stroke
and
peripheral
arterial
disease
continue
to
be
major
causes
of
premature
death,
disability
healthcare
expenditure
globally.
Preventing
the
accumulation
cholesterol-containing
atherogenic
lipoproteins
in
vessel
wall
is
central
any
strategy
prevent
ASCVD.
Advances
current
concepts
about
reducing
cumulative
exposure
apolipoprotein
B
(apo
B)
emergence
novel
therapies
provide
new
opportunities
better
The
present
update
World
Heart
Federation
Cholesterol
Roadmap
provides
a
conceptual
framework
for
development
national
policies
health
systems
approaches,
so
that
potential
roadblocks
cholesterol
management
thus
ASCVD
prevention
can
overcome.
Methods:
Through
review
published
guidelines
research
papers
since
2017,
consultation
with
committee
composed
experts
clinical
dyslipidaemias
low-and-middle
income
countries
(LMICs),
this
identifies
(1)
key
principles
effective
(2)
gaps
implementation
these
interventions
(knowledge-practice
gaps);
(3)
system
treatment
elevated
LMICs;
(4)
strategies
overcoming
these.
Results:
Reducing
future
burden
will
require
diverse
approaches
throughout
life-course.
These
include:
greater
focus
on
primordial
prevention;
availability
affordable
testing;
universal
screening
inherited
dyslipidaemias;
risk
stratification
moving
beyond
10-year
look
at
lifetime
adequate
estimators;
wider
cholesterol-lowering
which
should
include
statins
as
essential
medications
globally;
use
doses
potent
statin
regimens;
combination
ezetimibe
or
other
order
attain
maintain
robust
reductions
LDL-C
those
highest
risk.
Continuing
efforts
are
needed
literacy
both
public
providers,
utilising
multi-disciplinary
teams
applications
quantify
benefits
well
increased
adherence
therapies.
Conclusions:
adverse
effects
LDL-cholesterol
apo
containing
lipoprotein
result
preventable
by
different
strategies,
aimed
efficiently
tackling
atherosclerosis
stages
human
Preventive
therefore
updated
implement
policy,
lifestyle
changes
when
pharmacotherapies
earlier
investment
in,
shift
towards,
early
preventive
preserve
rather
than
treat
consequences
European Heart Journal,
Journal Year:
2023,
Volume and Issue:
44(39), P. 4157 - 4173
Published: Aug. 23, 2023
Cardiovascular
disease
is
the
leading
cause
of
death
in
women
and
men
globally,
with
most
due
to
atherosclerotic
cardiovascular
(ASCVD).
Despite
progress
during
last
30
years,
ASCVD
mortality
now
increasing,
fastest
relative
increase
middle-aged
women.
Missed
or
delayed
diagnosis
undertreatment
do
not
fully
explain
this
burden
disease.
Sex-specific
factors,
such
as
hypertensive
disorders
pregnancy,
premature
menopause
(especially
primary
ovarian
insufficiency),
polycystic
ovary
syndrome
are
also
relevant,
good
evidence
that
these
associated
greater
risk.
This
position
statement
from
European
Atherosclerosis
Society
focuses
on
well
sex-specific
effects
lipids,
including
lipoprotein(a),
over
life
course
which
impact
Women
disproportionately
impacted
(in
terms)
by
diabetes,
chronic
kidney
disease,
auto-immune
inflammatory
All
compounded
sociocultural
components
related
gender.
panel
stresses
need
identify
treat
modifiable
risk
factors
earlier
women,
especially
for
those
at
conditions,
reduce
unacceptably
high
